Merck CEO: Biotech valuations reflect optimism

10:17 AM ET Mon, 8 Dec 2014

Merck agreed to acquire Cubist Pharmaceuticals in a $9.5 billion deal. CNBC's Meg Tirrell discusses the price of the deal and patent challenges Merck may face.